4 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
% of synovial sarcoma tumors express MAGE-A4. MAGE-A4 expression based on ADAP samples and expression cut off criteria of ≥30% tumor cells at ≥2+ intensity
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
on Adaptimmune samples and expression cut-off criteria of ≥30% tumor cells at ≥2+ intensity; HLA-A2 expression of 41% based on Adaptimmune samples (1,043 patient
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
20 Nov 20
Regulation FD Disclosure
7:36am
criteria of ≥30% tumor cells at ≥2+ intensity; HLA-A2 expression of 41% based on ADAP samples (1,043 patient samples); Serum AFP expression ranges based
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
18 Jul 18
Other Events
5:01pm
billion cells in conjunction with a higher intensity preconditioning regimen, which, based on our data from the NY-ESO trials, may result in greater
- Prev
- 1
- Next